A planning study of radiotherapy dose escalation of PET-active tumour volumes in non-small cell lung cancer patients

Ditte Sloth Møller, Azza Ahmed Khalil, Marianne Marquard Knap, Ludvig Paul Muren, Lone Hoffmann

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Abstract

Patients with non-small cell lung cancer (NSCLC) have poor prognosis partly because of high local failure rates. Escalating the dose to the tumour may decrease the local failure rates and thereby, improve overall survival, but the risk of complications will limit the possibility to dose-escalate a broad range of patients. Escalating only PET-active areas of the tumour may increase the potential for reaching high doses for a variety of tumour sizes and locations.
Original languageEnglish
JournalActa Oncologica
Volume50
Issue6
Pages (from-to)883-8
Number of pages6
ISSN0284-186X
DOIs
Publication statusPublished - 2011

Keywords

  • Antineoplastic Combined Chemotherapy Protocols
  • Brachytherapy
  • Carboplatin
  • Carcinoma, Non-Small-Cell Lung
  • Chemoradiotherapy
  • Four-Dimensional Computed Tomography
  • Humans
  • Lung Neoplasms
  • Neoplasm Staging
  • Positron-Emission Tomography
  • Prognosis
  • Radiopharmaceuticals
  • Radiotherapy Planning, Computer-Assisted
  • Radiotherapy, Intensity-Modulated
  • Tomography, X-Ray Computed
  • Tumor Burden
  • Vinblastine

Fingerprint

Dive into the research topics of 'A planning study of radiotherapy dose escalation of PET-active tumour volumes in non-small cell lung cancer patients'. Together they form a unique fingerprint.

Cite this